Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 15/20 | 0.53 |
| ▸ | TDO2 | P48775 | 15/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21408574 | 0.83 | IDO1 (0.52) | IDO1TDO2CYP3A4CYP2C9FFAR4 | |
| SCHEMBL23271216 | 0.82 | IDO1 (0.52) | IDO1TDO2CYP3A4CYP2C9FFAR4 | |
| SCHEMBL23271205 | 0.81 | IDO1 (0.56) | IDO1TDO2CYP3A4CYP2C9FFAR4 | |
| SCHEMBL21408585 | 0.81 | IDO1 (0.67) | IDO1TDO2CYP3A4CYP2C9 | |
| SCHEMBL21430773 | 0.80 | IDO1 (0.52) | IDO1TDO2CYP3A4CYP2C9 | |
| SCHEMBL21138413 | 0.77 | IDO1 (0.50) | IDO1TDO2CYP3A4CYP2C9DAO | |
| Hydrochloric Acid SCHEMBL22635733 | 0.77 | IDO1 (0.47) | IDO1TDO2CYP3A4CYP2C9DAO | |
| SCHEMBL21408587 | 0.77 | IDO1 (0.54) | IDO1TDO2CYP3A4CYP2C9DAO | |
| SCHEMBL23271209 | 0.77 | IDO1 (0.49) | IDO1TDO2CYP3A4CYP2C9 | |
| SCHEMBL23271198 | 0.77 | IDO1 (0.64) | IDO1TDO2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210122757-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2021-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122757-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | IDO1 1/4885TDO2 9/4885CYP3A4 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.